Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
40.5M
-
Shares change
-
+9.84M
-
Total reported value, excl. options
-
$637M
-
Value change
-
+$153M
-
Put/Call ratio
-
1.73
-
Number of buys
-
88
-
Number of sells
-
-31
-
Price
-
$15.78
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2017
162 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2017.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.5M shares
of 108M outstanding shares and own 37.61% of the company stock.
Largest 10 shareholders include FMR LLC (7.97M shares), VANGUARD GROUP INC (3.47M shares), BlackRock Inc. (3.29M shares), BB BIOTECH AG (2.2M shares), WASATCH ADVISORS INC (1.97M shares), MILLENNIUM MANAGEMENT LLC (1.38M shares), RHENMAN & PARTNERS ASSET MANAGEMENT AB (1.18M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.11M shares), Hillhouse Capital Management, Ltd. (1M shares), and BVF INC/IL (950K shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.